{
    "clinical_study": {
        "@rank": "63849", 
        "arm_group": [
            {
                "arm_group_label": "Delafloxacin", 
                "arm_group_type": "Experimental", 
                "description": "900mg orally (2 x 450 mg tablets) administered once"
            }, 
            {
                "arm_group_label": "ceftriaxone", 
                "arm_group_type": "Active Comparator", 
                "description": "Ceftriaxone 250 mg intramuscular injection administered once"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of a single oral dose of delafloxacin\n      versus a single intramuscular injection of ceftriaxone in subjects with uncomplicated\n      cervical, urethral, rectal, or pharyngeal gonorrhea."
        }, 
        "brief_title": "Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Gonorrhea", 
        "condition_browse": {
            "mesh_term": "Gonorrhea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is a male or female 15 years of age or older.\n\n          -  Subject must have had 1 or more of the following occur:\n\n               1. gonorrhea with the NAAT or culture within the previous 14 days\n\n               2. unprotected genital contact within 14 days with a person confirmed  to be\n                  infected with gonorrhea,\n\n               3. gram-negative present in urogenital gram strain\n\n          -  Subject agrees to avoid unprotected sexual contact in order to minimize the risk of\n             gonorrhea reinfection\n\n          -  Subject must be in good health (ie, based on medical history), as determined by the\n             investigator.\n\n          -  In the opinion of the investigator, the subject must be able and willing to comply\n             with protocol requirements. The subject must agree to provide reliable, verifiable\n             contact information and agree to return for the Test-of-Cure Visit.\n\n          -  If a subject's age is 15 years to less than the legal age of consent,a written,\n             voluntarily signed assent must be obtained from the subject and a written,\n             voluntarily signed informed consent must be signed by the subject's parent or legal\n             guardian before the initiation of any study related procedures, unless the IRB/IEC\n             determines that parent/legal guardian consent is not required.\n\n        Exclusion Criteria:\n\n          -  Confirmed, or suspected, complicated or systemic gonococcal infection, such as pelvic\n             inflammatory disease, arthritis, or endocarditis.\n\n          -  Subject has taken one of the following products within 6 hours of the Entry Visit\n             that may interfere with the absorption of a quinolone antibiotic: magnesium/aluminum\n             antacids; sucralfate; Videx\u00ae (didanosine) chewable/buffered tablets; other highly\n             buffered drugs; or other products containing calcium, iron, or zinc.\n\n          -  Use of systemic or intravaginal antibiotics that are potentially effective against\n             gonorrhea within the 7 days prior to study drug administration for short-acting\n             antibiotics and within the 30 days prior to study drug administration for long-acting\n             antibiotics.\n\n          -  Subjects with a current or prior history of seizures, and subjects being treated with\n             drugs that are known to have a sizable potential of or reduce the threshold for\n             inducing seizures (eg, bupropion, theophylline, and tricyclic and tetracyclic\n             antidepressants).\n\n          -  Current use of systemic corticosteroid or immunosuppressive drugs.\n\n          -  Known significant immunosuppression (eg, CD4 cell count <200/mm3 or absolute\n             neutrophil count <500/mL).\n\n          -  Cytotoxic chemotherapy or radiation therapy during the previous 3 months.\n\n          -  Subject is co-infected with an additional sexually transmitted disease (STD) for\n             which treatment cannot be safely deferred until after the Test-of-Cure Visit unless\n             the treatment is not potentially effective against gonorrhea.\n\n          -  Subject has used an investigational drug or product within 30 days before study drug\n             dosing.\n\n          -  Medical history of Type 1 hypersensitivity to antibiotics of the quinolone or\n             cephalosporin classes.\n\n          -  Hysterectomized subjects without a cervix are ineligible."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "757", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015637", 
            "org_study_id": "ML-3341-304"
        }, 
        "intervention": [
            {
                "arm_group_label": "Delafloxacin", 
                "description": "1", 
                "intervention_name": "delafloxacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ceftriaxone", 
                "description": "2", 
                "intervention_name": "ceftriaxone", 
                "intervention_type": "Drug", 
                "other_name": "Rocephin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Ceftriaxone", 
                "Fluoroquinolones"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gonorrhea", 
            "N. gonorrhoeae", 
            "bacterial infection", 
            "Anti-Infective Agents", 
            "Anti-Bacterial Agents"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94103"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Melinta 304 Study"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30033"
                    }, 
                    "name": "Melinta 304 Study"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68114"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89109"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11203"
                    }, 
                    "name": "Melinta 304 Study"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11203"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27701"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43231"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97204"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erie", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16507"
                    }, 
                    "name": "Melinta 304 Study"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Melinta 304 Study Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Comparative Evaluation of the Single-dose Efficacy of Oral Delafloxacin Versus the Single-dose Efficacy of an Intramuscular Injection of Ceftriaxone in Subjects With Uncomplicated Urogenital Gonorrhea", 
        "overall_contact": {
            "email": "clinicaltrials@melinta.com", 
            "last_name": "Sue Cammarata, MD", 
            "phone": "203-848-5606"
        }, 
        "overall_official": {
            "affiliation": "Melinta Therapeutics, Inc.", 
            "last_name": "Sue Cammarata, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All subjects will return for the Test-of-Cure Visit.  However, culture and NAAT swabs will not be collected from anatomical sites with negative cultures and NAAT results, respectively, for N. gonorrhoeae from the Entry Visit. If results are not known, a swab will be collected at each anatomical site tested at the Entry Visit.", 
            "measure": "Microbiological outcome of urogenital gonorrhea", 
            "safety_issue": "No", 
            "time_frame": "Day 7 (\u00b1 3 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015637"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Microbiological response at all anatomical sites", 
                "safety_issue": "No", 
                "time_frame": "Day 7 (\u00b1 3 days)"
            }, 
            {
                "measure": "Resolution of signs and symptoms", 
                "safety_issue": "No", 
                "time_frame": "Day 7 (\u00b1 3 days)"
            }
        ], 
        "source": "Melinta Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Melinta Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}